tradingkey.logo
tradingkey.logo

Ekso Bionics Holdings Inc

EKSO
10.280USD
-0.620-5.69%
Close 03/30, 16:00ETQuotes delayed by 15 min
3.39MMarket Cap
LossP/E TTM

Ekso Bionics Holdings Inc

10.280
-0.620-5.69%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Ekso Bionics Holdings Inc

Currency: USD Updated: 2026-03-27

Key Insights

Ekso Bionics Holdings Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 117 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Ekso Bionics Holdings Inc's Score

Industry at a Glance

Industry Ranking
117 / 208
Overall Ranking
279 / 4542
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Ekso Bionics Holdings Inc Highlights

StrengthsRisks
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. It operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.
Growing
The company is in a growing phase, with the latest annual income totaling USD 12.80M.
Undervalued
The company’s latest PE is -2.07, at a low 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 35.45K shares of this stock.

Analyst Rating

Based on 2 analysts
Buy
Current Rating
9.500
Target Price
-12.84%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Ekso Bionics Holdings Inc is 5.65, ranking 193 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 3.14M, representing a year-over-year decrease of 38.31%, while its net profit experienced a year-over-year decrease of 36.95%.

Score

Industry at a Glance

Previous score
5.65
Change
0

Financials

4.97

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

7.33

Operational Efficiency

2.72

Growth Potential

6.12

Shareholder Returns

7.11

Ekso Bionics Holdings Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Ekso Bionics Holdings Inc is 8.58, ranking 16 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -2.07, which is -94.46% below the recent high of -0.11 and -36.93% above the recent low of -2.83.

Score

Industry at a Glance

Previous score
8.58
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 117/208
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Ekso Bionics Holdings Inc is 7.00, ranking 153 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 7.75, with a high of 9.50 and a low of 6.00.

Score

Industry at a Glance

Previous score
7.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts
Buy
Current Rating
9.500
Target Price
-6.40%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

92
Total
4
Median
7
Average
Company name
Ratings
Analysts
Ekso Bionics Holdings Inc
EKSO
2
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
36
Edwards Lifesciences Corp
EW
34
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
29
1
2
3
...
19

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Ekso Bionics Holdings Inc is 6.86, ranking 56 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 12.48 and the support level at 8.84, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
7.27
Change
-0.41

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(4)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.339
Neutral
RSI(14)
45.093
Neutral
STOCH(KDJ)(9,3,3)
21.226
Neutral
ATR(14)
0.916
Low Volatility
CCI(14)
-88.121
Neutral
Williams %R
95.714
Oversold
TRIX(12,20)
0.143
Sell
StochRSI(14)
0.000
Sell
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
10.626
Sell
MA10
10.671
Sell
MA20
11.009
Sell
MA50
10.136
Buy
MA100
7.862
Buy
MA200
5.955
Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Ekso Bionics Holdings Inc is 3.00, ranking 135 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 8.72%, representing a quarter-over-quarter decrease of 23.62%. The largest institutional shareholder is The Vanguard, holding a total of 35.45K shares, representing 0.99% of shares outstanding, with 52.75% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Davis (Scott Gerald)
78.95K
+254.58%
The Vanguard Group, Inc.
Star Investors
35.45K
+196.31%
Li (Kecheng)
30.73K
+105.11%
Lathan (Corinna)
25.61K
+159.61%
Cloyd (Mary Ann)
25.23K
+166.00%
Geode Capital Management, L.L.C.
14.93K
+23.74%
1
2

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ekso Bionics Holdings Inc is 1.26, ranking 193 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.78. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
1.26
Change
0
Beta vs S&P 500 index
0.78
VaR
+7.64%
240-Day Maximum Drawdown
+63.03%
240-Day Volatility
+134.29%

Return

Best Daily Return
60 days
+93.77%
120 days
+93.77%
5 years
+93.77%
Worst Daily Return
60 days
-18.34%
120 days
-18.34%
5 years
-28.62%
Sharpe Ratio
60 days
+1.95
120 days
+1.43
5 years
-0.01

Risk Assessment

Maximum Drawdown
240 days
+63.03%
3 years
+93.94%
5 years
+93.94%
Return-to-Drawdown Ratio
240 days
+1.35
3 years
-0.20
5 years
+0.18
Skewness
240 days
+5.52
3 years
+3.19
5 years
+3.26

Volatility

Realised Volatility
240 days
+134.29%
5 years
+162.65%
Standardised True Range
240 days
+6.09%
5 years
+9.14%
Downside Risk-Adjusted Return
120 days
+445.50%
240 days
+445.50%
Maximum Daily Upside Volatility
60 days
+78.30%
Maximum Daily Downside Volatility
60 days
+67.31%

Liquidity

Average Turnover Rate
60 days
+0.54%
120 days
+6.17%
5 years
--
Turnover Deviation
20 days
-93.97%
60 days
-80.82%
120 days
+119.29%

Peer Comparison

Healthcare Equipment & Supplies
Ekso Bionics Holdings Inc
Ekso Bionics Holdings Inc
EKSO
5.90 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc
TMO
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bioventus Inc
Bioventus Inc
BVS
8.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
Anika Therapeutics Inc
ANIK
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
Edwards Lifesciences Corp
EW
8.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI